NAROPIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NAROPIN (NAROPIN).
Ropivacaine blocks sodium ion channels in neuronal cell membranes, inhibiting the conduction of nerve impulses.
| Metabolism | Primarily hepatic via CYP1A2 and CYP3A4; metabolized to 3-hydroxy-ropivacaine and other metabolites. |
| Excretion | Renal: 86-93% as metabolites (including 3-hydroxyropivacaine, 4-hydroxyropivacaine, and 2',6'-pipecoloxylidide), <1% unchanged. Biliary/fecal: <10% collectively, primarily as metabolites. |
| Half-life | Terminal elimination half-life: 4.2 ± 1.1 hours (adults) for ropivacaine. Clinical context: prolonged half-life in neonates (up to 12-18 hours) due to immature hepatic clearance; consider accumulation with continuous infusion in renal impairment (though minimal unchanged drug). |
| Protein binding | 94% bound primarily to alpha-1-acid glycoprotein (AAG) and, to a lesser extent, albumin. Note: binding is concentration-dependent; at high concentrations (above 1 µg/mL), binding decreases, increasing free fraction and potential toxicity. |
| Volume of Distribution | Steady-state volume of distribution (Vdss): 0.59 L/kg (range 0.41-0.84 L/kg) in adults. Clinical meaning: moderate distribution, reflecting distribution to well-perfused tissues; higher in neonates (1.4-2.5 L/kg) due to increased body water and lower AAG levels. |
| Bioavailability | Epidural: 98% (systemic absorption is nearly complete). Intrathecal: ~100% (directly into CSF). Subcutaneous infiltration: ~100% (absorbed into systemic circulation). Oral: not available (low bioavailability due to extensive first-pass metabolism). |
| Onset of Action | Epidural (lumbar): 15-30 minutes for surgical anesthesia. Peripheral nerve block: 15-30 minutes (depending on technique). Subcutaneous infiltration: 1-5 minutes. Intrathecal: 5-15 minutes. |
| Duration of Action | Epidural (surgical anesthesia): 2-6 hours (dose-dependent). Peripheral nerve block: 4-12 hours (with epinephrine may extend to 12-18 hours). Subcutaneous infiltration: 2-4 hours. Clinical notes: duration increases with higher concentration (0.5% > 0.2%) and addition of epinephrine (prolongs sensory block but not motor). |
Epidural administration: Initial dose 20-30 mL of 0.5% solution (100-150 mg) followed by 10-15 mL/hour of 0.2% solution for continuous infusion. Maximum single dose: 200 mg. Maximum daily dose: 400 mg.
| Dosage form | SOLUTION |
| Renal impairment | No specific dose adjustment required for GFR ≥30 mL/min. For GFR <30 mL/min, use with caution and consider reducing dose by 25-50% due to potential accumulation of metabolites. |
| Liver impairment | Child-Pugh A: No adjustment necessary. Child-Pugh B: Reduce dose by 50% and monitor for toxicity. Child-Pugh C: Contraindicated due to risk of severe toxicity. |
| Pediatric use | Epidural bolus: 0.5-1 mg/kg of 0.2-0.5% solution. Continuous infusion: 0.2-0.4 mg/kg/hour of 0.1-0.2% solution. Maximum single dose: 2 mg/kg. Not recommended for infants under 1 year due to limited data. |
| Geriatric use | Initial dose should be reduced by 20-30% due to decreased clearance and increased sensitivity. Titrate carefully with lower infusion rates (e.g., 5-10 mL/hour of 0.2% solution) and monitor for hypotension and bradycardia. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NAROPIN (NAROPIN).
| Breastfeeding | Ropivacaine is excreted in human milk in small amounts. Based on limited data, the milk-to-plasma (M/P) ratio is approximately 0.2 to 0.4. The estimated daily dose to a breastfeeding infant is less than 10% of the maternal weight-adjusted dose, making adverse effects unlikely. However, caution is advised, especially in neonates or preterm infants due to immature metabolism. The American Academy of Pediatrics considers ropivacaine compatible with breastfeeding. |
| Teratogenic Risk | Naropin (ropivacaine) is a local anesthetic of the amide type. No adequate and well-controlled studies in pregnant women. Animal studies have not shown teratogenic effects at doses up to 1.3 mg/kg (rabbit) and 7.3 mg/kg (rat). However, ropivacaine crosses the placenta rapidly and may cause fetal bradycardia, acidosis, and central nervous system depression if high maternal levels occur. First trimester: risk cannot be ruled out, but no evidence of structural anomalies. Second and third trimesters: potential for fetal distress due to maternal hypotension or uterine hypoperfusion from sympathetic blockade; use only if clearly needed. |
■ FDA Black Box Warning
Not approved for use in children under 12 for neuraxial anesthesia due to risk of serious adverse effects.
| Serious Effects |
["Hypersensitivity to ropivacaine or amide-type local anesthetics","Severe hypotension","Severe bradycardia","Neuraxial anesthesia in patients with coagulopathy or increased bleeding risk"]
| Precautions | ["Risk of cardiac arrest and seizures with high doses or inadvertent intravascular injection","May cause methemoglobinemia"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal heart rate, blood pressure, and oxygen saturation continuously during administration. Fetal heart rate monitoring should be performed when possible, especially during epidural or spinal anesthesia. Observe for signs of maternal hypotension, which can reduce uterine blood flow. Monitor for fetal bradycardia, as local anesthetics can cross the placenta. After delivery, monitor neonate for signs of local anesthetic toxicity (e.g., apnea, bradycardia, seizures). |
| Fertility Effects | No specific studies on human fertility. Animal studies (rat) showed no significant effects on male or female fertility at doses up to 7.3 mg/kg. It is not known whether ropivacaine affects human fertility. Based on mechanism, no expected impact on fertility when used at recommended doses. |